1-20 of 43
Rinath Jeselsohn
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 7225: The secreted cytokine Chitinase 3-like-1 promotes breast cancer metastasis

Free
Adeline Masse, Tarek Taifour, Yu Gu, Virginie Sanguin-Gendreau, Dongmei Zuo, Bin Xiao, Hailey Proud, Nancy U. Lin, Melissa E. Hughes, Kalie Smith, Rinath Jeselsohn, William J. Muller
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 7225.
https://doi.org/10.1158/1538-7445.AM2025-7225
Published: 21 April 2025
View articletitled, Abstract 7225: The secreted cytokine Chitinase 3-like-1 promotes breast cancer metastasis
Journal Articles

Abstract 1181: Combined inhibition of KAT6 and menin reverses estrogen receptor-driven gene expression programs in breast cancer

Free
Sarah Naomi Olsen, Bryn Anderson, Charles Hatton, Myles Brown, Rinath Jeselsohn, Eneda Toska, Scott Armstrong
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 1181.
https://doi.org/10.1158/1538-7445.AM2025-1181
Published: 21 April 2025
View articletitled, Abstract 1181: Combined inhibition of KAT6 and menin reverses estrogen receptor-driven gene expression programs in breast cancer
Journal Articles

Abstract 1172: An estrogen receptor signaling transcriptional program linked to immune evasion in human hormone receptor-positive breast cancer

Free
Kenichi Shimada, Daniel E. Michaud, Yvonne X. Cui, Kelly Zheng, Jonathan Goldberg, Zhenlin Ju, Stuart J. Schnitt, Ricardo Pastorello, Lukas D. Kania, John Hoffer, Jeremy L. Muhlich, Nhan Hyun, Robert Krueger, Alexander Gottlieb, Adam Nelson, Carlos W. Wanderley, Gabriella Antonellis, Sandra S. McAllister, Sara M. Tolaney, Adrienne G. Waks, Rinath Jeselsohn, Peter K. Sorger, Judith Agudo, Elizabeth A. Mittendorf, Jennifer L. Guerriero
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 1172.
https://doi.org/10.1158/1538-7445.AM2025-1172
Published: 21 April 2025
View articletitled, Abstract 1172: An estrogen receptor signaling transcriptional program linked to immune evasion in human hormone receptor-positive breast cancer
Journal Articles

Abstract GS03-09: Characterization and proposed therapeutic exploitation of fusion RNAs in metastatic breast cancers

Free
Nolan Priedigkeit, Alinés Lebrón-Torres, Janny Liao, Jean-Baptiste Alberge, Stefania Morganti, Jakob Weiss, Jorge Gomez Tejeda Zanudo, Albert Grinshpun, Melissa Hughes, Karla Helvie, Kerry Sendrick, Kyleen Nguyen, Sarah Strauss, Janet Files, Maxwell Lloyd, Nikhil Wagle, Chip Stewart, Eric Winer, Bruce Johnson, Yvonne Li, Rinath Jeselsohn, Sara Tolaney, Daniel Abravanel, Nancy Lin, Heather Parsons, Gad Getz, Steffi Oesterreich, Adrian Lee, Todd Golub
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): GS03-09.
https://doi.org/10.1158/1538-7445.SABCS23-GS03-09
Published: 02 May 2024
View articletitled, Abstract GS03-09: Characterization and proposed therapeutic exploitation of fusion RNAs in metastatic breast cancers
Journal Articles

Abstract PS12-06: A phase 2 study of abemaciclib monotherapy for patients with retinoblastoma-positive (Rb+), triple-negative metastatic breast cancer

Free
Shom Goel, Bojana Jovanović, Xiangying Chu, Melissa Hughes, Ayesha Mohammed-Abreu, Julie Kasparian, Timothy Erick, Molly DiLullo, Eileen Wrabel, Rinath Jeselsohn, Nabihah Tayob, Stuart Schnitt, Nancy Lin, Sara Tolaney
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PS12-06.
https://doi.org/10.1158/1538-7445.SABCS23-PS12-06
Published: 02 May 2024
View articletitled, Abstract PS12-06: A phase 2 study of abemaciclib monotherapy for patients with retinoblastoma-positive (Rb+), triple-negative metastatic breast cancer
Journal Articles

Abstract PO3-01-09: Results of a prospective observational study evaluating the impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR+/HER2- breast cancer

Free
Chiara Corti, Xiangying Chu, Pedro Exman, Danielle Kline, Nolan Priedigkeit, Nabihah Tayob, Erica Mayer, Adrienne Waks, Melissa Hughes, Antonio Giordano, Giuseppe Curigliano, Nancy Lin, Tari King, Rinath Jeselsohn, Deborah Dillon, Elizabeth Mittendorf, Sara Tolaney
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO3-01-09.
https://doi.org/10.1158/1538-7445.SABCS23-PO3-01-09
Published: 02 May 2024
View articletitled, Abstract PO3-01-09: Results of a prospective observational study evaluating the impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR+/HER2- breast cancer
Journal Articles

Abstract PS12-02: Exploration of ctDNA Dynamics in the PACE Trial: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for HR+/HER2- Metastatic Breast Cancer

Free
Rinath Jeselsohn, Jingxin Fu, Yue Ren, Reshma Mahtani, Cynthia Ma, Angela DeMichele, Massimo Cristofanilli, Jane Meisel, Kathy Miller, Yara Abdou, Elizabeth Riley, Rubina Qamar, Priyanka Sharma, Sonya Reid, Naomi Ko, Yuan Liu, Harold Burstein, Michelle DeMeo, Sara Tolaney, Erica Mayer
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PS12-02.
https://doi.org/10.1158/1538-7445.SABCS23-PS12-02
Published: 02 May 2024
View articletitled, Abstract PS12-02: Exploration of ctDNA Dynamics in the PACE Trial: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for HR+/HER2- Metastatic Breast Cancer
Journal Articles

Abstract PS08-09: Impact of HER2 expression dynamics on the real-world activity of trastuzumab deruxtecan for metastatic breast cancer (RELIEVE)

Free
Paolo Tarantino, Melissa Hughes, Ross Kusmick, Laura Alder, Alyssa Pereslete, Laura Noteware, Heather Moore, Amanda Van Swearingen, Tianyu Li, Hersh Gupta, Kalie Smith, Stefania Morganti, Janet Files, Kerry Sendrick, Simone Buck, Deborah Dillon, Rinath Jeselsohn, Yvonne Li, Andrew Cherniack, Aleix Prat, Nay Nwe Nyein Chan, David Rimm, Giuseppe Curigliano, Sarah Sammons, Carey Anders, Nancy Lin, Sara Tolaney
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PS08-09.
https://doi.org/10.1158/1538-7445.SABCS23-PS08-09
Published: 02 May 2024
View articletitled, Abstract PS08-09: Impact of HER2 expression dynamics on the real-world activity of trastuzumab deruxtecan for metastatic breast cancer (RELIEVE)
Journal Articles

Abstract PS15-03: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib in ER–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: phase 1b cohort

Free
Erika Hamilton, Rinath Jeselsohn, Sara Hurvitz, Dejan Juric, Hyo Han, Melinda Telli, George Zahrah, Rita Nanda, Yuanyuan Zhang, Weiwei Tan, Elizabeth Duperret, Eric Zhi, Cecile Mather, Anne Schott
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PS15-03.
https://doi.org/10.1158/1538-7445.SABCS23-PS15-03
Published: 02 May 2024
View articletitled, Abstract PS15-03: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib in ER–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: phase 1b cohort
Journal Articles

Abstract PO2-27-12: Genomic determinants of benefit to nivolumab (NIVO) plus low dose ipilimumab (IPI) among patients (pts) with hypermutated HER2-negative metastatic breast cancer (MBC): results of NIMBUS trial

Free
Romualdo Barroso-Sousa, Tyler Chinsky, Tianyu Li, Sangeetha Reddy, Leisha Emens, Beth Overmoyer, Saud AlDubayan, Hoyin Chu, Paulina Lange, Julie Kasparian, Ameer Basta, Molly DiLullo, Victoria Attaya, Melissa Hughes, Nancy Lin, Nabihah Tayob, Rinath Jeselsohn, Elizabeth Mittendorf, Sara Tolaney
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO2-27-12.
https://doi.org/10.1158/1538-7445.SABCS23-PO2-27-12
Published: 02 May 2024
View articletitled, Abstract PO2-27-12: Genomic determinants of benefit to nivolumab (NIVO) plus low dose ipilimumab (IPI) among patients (pts) with hypermutated HER2-negative metastatic breast cancer (MBC): results of NIMBUS trial
Journal Articles

Abstract PS15-09: Imlunestrant monotherapy and in combination with abemaciclib, with or without an aromatase inhibitor, in estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC): updated results from the EMBER study

Free
Komal Jhaveri, Elgene Lim, Rinath Jeselsohn, Cynthia Ma, Erika Hamilton, Cynthia Osborne, Manali Bhave, Peter Kaufman, J. Thaddeus Beck, Luis Manso, Ritesh Parajuli, Hwei-Chung Wang, Jessica Tao, Ajay Dhakal, Jean-Yves Pierga, Yen-Shen Lu, Tim Larson, Yolanda Jerez Gilarranz, Roohi Ismail-Khan, Francesca Bacchion, Claudia Karacsonyi, Yujia Li, Shawn T. Estrem, Bastien Nguyen, Muralidhar Beeram
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PS15-09.
https://doi.org/10.1158/1538-7445.SABCS23-PS15-09
Published: 02 May 2024
View articletitled, Abstract PS15-09: Imlunestrant monotherapy and in combination with abemaciclib, with or without an aromatase inhibitor, in estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC): updated results from the EMBER study
Journal Articles

Abstract PO3-05-08: Updated results from VERITAC evaluating vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in ER–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer

Free
Sara Hurvitz, Anne Schott, Cynthia Ma, Rita Nanda, George Zahrah, Natasha Hunter, Antoinette Tan, Melinda Telli, Jesus Anampa Mesias, Rinath Jeselsohn, Pamela Munster, Eric Zhi, Elizabeth Duperret, Cecile Mather, Erika Hamilton, Hyo Han
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO3-05-08.
https://doi.org/10.1158/1538-7445.SABCS23-PO3-05-08
Published: 02 May 2024
View articletitled, Abstract PO3-05-08: Updated results from VERITAC evaluating vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in ER–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer
Journal Articles

Abstract PO3-04-13: SUMIT-ELA: Phase 1b/2 combination of cyclin-dependent kinase 7 inhibitor (CDK7i) samuraciclib and selective estrogen receptor degrader (SERD) elacestrant in advanced hormone receptor positive (HR+) breast cancer after CDK4/6i

Free
Amita Patnaik, Silvia Antolin Novoa, Meritxell Bellet- Ezquerra, Francois-Clement Bidard, Valentina Boni, Maxime Brunet, Mario Campone, Carlos Garay, Raquel Gómez-Bravo, Sacha Howell, Rinath Jeselsohn, Simon Lord, Paolo Mazzei, Maria De Miguel, Erin Roesch, Agostina Stradella, Helene Vanacker, Cecile Vicier, Seth Wander, Glen Clack, Stuart McIntosh
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO3-04-13.
https://doi.org/10.1158/1538-7445.SABCS23-PO3-04-13
Published: 02 May 2024
View articletitled, Abstract PO3-04-13: SUMIT-ELA: Phase 1b/2 combination of cyclin-dependent kinase 7 inhibitor (CDK7i) samuraciclib and selective estrogen receptor degrader (SERD) elacestrant in advanced hormone receptor positive (HR+) breast cancer after CDK4/6i
Journal Articles

Abstract PO5-26-07: Surgery for Invasive Lobular Carcinoma: A Patient Experience Survey from the Lobular Breast Cancer Alliance

Free
Laurie Hutcheson, Janice Axelrod, Tracy Cushing, Colleen Fitzwater, Rinath Jeselsohn, Gitte Joergensen, Maria Karsten, Miranda Kimm, Megan Kruse, Theresa Langdon, Julia Levine, Mason Mitchell-Daniels, Rita Mukhtar, Barbara Neilsen, Shani Paluch-Shimon, Therese Pross
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO5-26-07.
https://doi.org/10.1158/1538-7445.SABCS23-PO5-26-07
Published: 02 May 2024
View articletitled, Abstract PO5-26-07: Surgery for Invasive Lobular Carcinoma: A Patient Experience Survey from the Lobular Breast Cancer Alliance
Journal Articles

Abstract 3707: Characterization of estrogen receptor expression on CTCs during CDK4/6i treatment in HR+/HER2- metastatic breast cancer: Results from the PACE phase II study

Free
Mara Serena Serafini, Carolina Reduzzi, Lorenzo Gerratana, Rinath Jeselsohn, Reshma L. Mahtani, Cynthia X. Ma, Angela DeMichele, Jane Lowe Meisel, Kathy D. Miller, Yara Abdou, Elizabeth C. Riley, Rubina Qamar, Priyanka Sharma, Sonya Reid, Harold J. Burstein, Sara M. Tolaney, Michelle K. DeMeo, Yuan Liu, Eric Gauthier, Yue Ren, Meredith M. Regan, Huiping Liu, Erica L. Mayer, Massimo Cristofanilli
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3707.
https://doi.org/10.1158/1538-7445.AM2024-3707
Published: 22 March 2024
View articletitled, Abstract 3707: Characterization of estrogen receptor expression on CTCs during CDK4/6i treatment in HR+/HER2- metastatic breast cancer: Results from the PACE phase II study
Journal Articles

Abstract 109: Identification of tumor-intrinsic and extrinsic mechanisms of T cell exclusion in estrogen receptor-positive (ER+) breast cancer through integration of bulk and single-cell transcriptome and spatial analysis

Free
Kenichi Shimada, Yvonne X. Cui, Daniel Michaud, Kelly F. Zheng, Jonathan Goldberg, Ricardo Pastorello, Lukas Kania, Sandra S. McAllister, Sara M. Tolaney, Adrienne Waks, Rinath Jeselsohn, Peter K. Sorger, Judith Agudo, Jennifer L. Guerriero, Elizabeth A. Mittendorf
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 109.
https://doi.org/10.1158/1538-7445.AM2024-109
Published: 22 March 2024
View articletitled, Abstract 109: Identification of tumor-intrinsic and extrinsic mechanisms of T cell exclusion in estrogen receptor-positive (ER+) breast cancer through integration of bulk and single-cell transcriptome and spatial analysis
Journal Articles

Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

Open Access
Francisco Hermida-Prado, Yingtian Xie, Shira Sherman, Zsuzsanna Nagy, Douglas Russo, Tara Akhshi, Zhengtao Chu, Avery Feit, Marco Campisi, Minyue Chen, Agostina Nardone, Cristina Guarducci, Klothilda Lim, Alba Font-Tello, Irene Lee, Juana García-Pedrero, Israel Cañadas, Judith Agudo, Ying Huang, Tal Sella, Qingchun Jin, Nabihah Tayob, Elizabeth A. Mittendorf, Sara M. Tolaney, Xintao Qiu, Henry Long, William F. Symmans, Jia-Ren Lin, Sandro Santagata, Isabelle Bedrosian, Denise A. Yardley, Ingrid A. Mayer, Edward T. Richardson, Giacomo Oliveira, Catherine J. Wu, Eugene F. Schuster, Mitch Dowsett, Alana L. Welm, David Barbie, Otto Metzger, Rinath Jeselsohn
Journal: Cancer Research
Cancer Res (2023) 83 (19): 3284–3304.
https://doi.org/10.1158/0008-5472.CAN-23-1711
Published: 02 October 2023
View articletitled, Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Open the PDF for Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract 3875: Evaluation of resistance mechanisms to ARV471, an ER-targeted PROTAC

Free
Delia Margaret Friel, Zachary Sandusky, Yijia Jiang, Xintao Qiu, Rong Li, Henry Long, Rinath Jeselsohn, Myles Brown
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3875.
https://doi.org/10.1158/1538-7445.AM2023-3875
Published: 04 April 2023
View articletitled, Abstract 3875: Evaluation of resistance mechanisms to ARV471, an ER-targeted PROTAC
Journal Articles

Abstract HER2-05: HER2-05 Comprehensive genomic characterization of HER2-low breast cancer

Free
Paolo Tarantino, Hersh V. Gupta, Melissa E. Hughes, Janet L. Files, Sarah Strauss, Gregory Kirkner, Anne-Marie Feeney, Yvonne Y. Li, Ana C. Garrido-Castro, Romualdo Barroso-Sousa, Brittany Bychkovsky, Laura MacConaill, Neal Lindeman, Bruce Johnson, Matthew Meyerson, Sheheryar Kabraji, Rinath Jeselsohn, Xintao Qiu, Rong Li, Henry W. Long, Eric Winer, Deborah A. Dillon, Giuseppe Curigliano, Andrew Cherniack, Sara Tolaney, Nancy U. Lin
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): HER2-05.
https://doi.org/10.1158/1538-7445.SABCS22-HER2-05
Published: 01 March 2023
View articletitled, Abstract HER2-05: HER2-05 Comprehensive genomic characterization of HER2-low breast cancer
Journal Articles

Abstract GS3-07: GS3-07 Clonal evolution and mechanisms of acquired resistance to CDK4/6 inhibitors in ER-wild type and ER-mutant breast cancer

Free
Cristina Guarducci, Simona Cristea, Avery Feit, Sergey Naumenko, Agostina Nardone, Wen Ma, Douglas Russo, Gabriella Cohen Feit, Ariel Feiglin, Francisco Hermida-Prado, Shira Sherman, Myles Brown, Franziska Michor, Rinath Jeselsohn
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): GS3-07.
https://doi.org/10.1158/1538-7445.SABCS22-GS3-07
Published: 01 March 2023
View articletitled, Abstract GS3-07: GS3-07 Clonal evolution and mechanisms of acquired resistance to CDK4/6 inhibitors in ER-wild type and ER-mutant breast cancer